CSC Pharmaceuticals, the Austrian-based arm of the Angelini Group in central and eastern Europe will launch food supplements targeting breast inflammation (mastitis) that is estimated to affect about 15% of women during breast feeding.
Austria, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania and Slovakia will be the first markets for the products from CSC.
The World Health Organization (WHO) has warned of mastitis causing the early abandonment of breast feeding. It is most typically treated with antibiiotics.
Biosearch has for several years been developing the Hereditum Lactobacillus Fermentum Lc40 strain it isolated from human breast milk.
"With this agreement, we make the product available for a big population of breastfeeding mothers and the health of their infants in many countries across Europe,” said Biosearch managing director, Jose M Roset.
Biosearch in 2012 inked another deal with Angelini Farmacéutica SA, the Spanish arm of Angelini Group, to produce food supplements sold over-the-counter in pharmacies throughout Spain.
It also has a deal with Australian firm Pure Medic for a product called Qiara.
Biosearch says the ingredient is suitable for formulation into different formats like pills, capsules and powder sticks.
Breast-milked derived L. salivarius and L. fermentum were used in a trial published in Clinical Infectious Diseases in 2010 (50(12):1551–1558) that showed mastitis benefits.